Scholarlink

<p>Self-guided virtual reality exposure therapy (SGVRET) may offer a scalable approach for social anxiety, but its independent effects remain uncertain. This systematic review and meta-analysis was conducted in accordance with PRISMA and Cochrane methodological guidance. Searches were conducted in PubMed, Embase, Web of Science, the Cochrane Library, and Scopus, and 13 randomized controlled trials were included. Results indicate that SGVRET was associated with a significant reduction in public speaking anxiety (PSAS; SMD = −1.47, 95% CI [−2.56, −0.37]). For overall social anxiety severity (LSAS/LSAS-SR), the pooled estimate favored SGVRET but did not reach statistical significance and showed substantial heterogeneity (SMD = −0.69, 95% CI [−1.50, 0.13]). No statistically significant improvements were detected for social phobia symptoms (SPS/SPS-6; SMD = −0.17, 95% CI [−0.67, 0.32]) or social interaction anxiety (SIAS/SIAS-6; SMD = −0.35, 95% CI [−1.07, 0.37]). However, most included trials had a high risk of bias, limiting the robustness of the evidence. Overall, the findings suggest that SGVRET may hold potential for performance-related social anxiety, particularly public speaking anxiety, but the current evidence remains preliminary and requires confirmation in larger, rigorous trials.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Systematic review and meta analysis of self guided virtual reality exposure therapy for social anxiety

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年8月4日

查看全文
  • Yiyuan Li,
  • Jifeng Shen,
  • Guanghui Huang

摘要

Self-guided virtual reality exposure therapy (SGVRET) may offer a scalable approach for social anxiety, but its independent effects remain uncertain. This systematic review and meta-analysis was conducted in accordance with PRISMA and Cochrane methodological guidance. Searches were conducted in PubMed, Embase, Web of Science, the Cochrane Library, and Scopus, and 13 randomized controlled trials were included. Results indicate that SGVRET was associated with a significant reduction in public speaking anxiety (PSAS; SMD = −1.47, 95% CI [−2.56, −0.37]). For overall social anxiety severity (LSAS/LSAS-SR), the pooled estimate favored SGVRET but did not reach statistical significance and showed substantial heterogeneity (SMD = −0.69, 95% CI [−1.50, 0.13]). No statistically significant improvements were detected for social phobia symptoms (SPS/SPS-6; SMD = −0.17, 95% CI [−0.67, 0.32]) or social interaction anxiety (SIAS/SIAS-6; SMD = −0.35, 95% CI [−1.07, 0.37]). However, most included trials had a high risk of bias, limiting the robustness of the evidence. Overall, the findings suggest that SGVRET may hold potential for performance-related social anxiety, particularly public speaking anxiety, but the current evidence remains preliminary and requires confirmation in larger, rigorous trials.